Akèy › Maladi fwa steatotik › New York
Etid klinik pou Maladi fwa steatotik nan New York
17 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan New York.
Vil nan New York
Tèks ofisyèl etid la (Anglè)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, New York
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- New York Presbyterian/Weill Cornell, New York
- Columbia University Iriving School of Medicine, New York
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Columbia University Irving Medical Center, New York
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Research Foundation of SUNY - University of Buffalo, Buffalo
- NYU Langone Health, New York
- IMA Clinical Research Manhattan, New York
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Buffalo
- Akero Clinical Study Site, Manhasset
- Akero Clinical Study Site, New York
- ak 3 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, East Syracuse
- GSK Investigational Site, New York
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT07221188A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Albany
- 89bio Clinical Study Site, Carmel
- 89bio Clinical Study Site, New York
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Albany
- 89bio Clinical Study Site, New York
- 89bio Clinical Study Site, New York
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 3, 2026 · NCT06419374Human Models of Selective Insulin Resistance: Alpelisib, Part I
- Columbia University Irving Medical Center, New York
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Aug 24, 2026 · NCT06354088A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, New York
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Aug 3, 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, East Syracuse
- GSK Investigational Site, New York
- GSK Investigational Site, New York
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, New York
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Jul 8, 2026 · NCT06920043Effect of Insulin Lowering on Lipogenesis
- Columbia University Irving Medical Center, New York
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Jul 6, 2026 · NCT07403604Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- Icahn School of Medicine at Mount Sinai, New York
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou May 19, 2026 · NCT04054310Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
- Weill Cornell Medicine, New York
Ap rekriteVolontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Feb 27, 2026 · NCT05332613High Fructose Diet, the Gut Microbiome, and Metabolic Health
- Mount Sinai Morningside, New York
Ap rekriteVolontè an sante akeyi
Laj 25 a 45 · Tout sèks · Mizajou Dec 17, 2025 · NCT06329544Blood Collection Biorepository for Liver Disease Research
- University at Buffalo, Buffalo General Medical Center, Buffalo
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 7 ak plis · Tout sèks · Mizajou Aug 27, 2025 · NCT03025074Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.